BGE-102
Small Molecule Target: NLRP3
BioAge Labs
Most recent annual filing: 2026-03-24
- BGE-102 Ph1 startMid-2026BGE-102 Ph1 start, Mid-2026, notable
- QUELL-DME Ph1 startMid-2026QUELL-DME Ph1 start, Mid-2026, routine
- BGE-102 topline2H 2026BGE-102 topline, 2H 2026, thesis-defining
- APJ agonist program IND filingYE 2026APJ agonist program IND filing, YE 2026, notable
- BGE-102 DME Ph1 toplineMid-2027BGE-102 DME Ph1 topline, Mid-2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
Technology platforms
BioAge Longevity Map · Eli Lilly and Company
Human aging biology target discovery platform combining longitudinal multi-omic molecular profiling of aging cohorts with data science analysis to identify novel drug targets for cardiometabolic and metabolic diseases; focus on chronic cardiometabolic diseases
BioAge Longevity Map · Novartis Pharma AG
Human aging biology target discovery platform; ongoing target discovery collaboration with Novartis focused on identifying novel cardiometabolic disease targets
Discontinued (1)
- azelaprag — Obesity · terminated due to liver transaminitis observations in some patients in the azelaprag arms of the STRIDES Phase 2 clinical trial
Biotech Distilled coverage (2)
- 2026-08-06 UPDATE: BioAge Labs (BIOA) - The Clock Is Set, The Stock Is Not 🔒 Paid
- 2026-05-18 BioAge Labs (BIOA) - Scientific Deep Dive for BGE-102 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.